CN101479599A - 使用生物标记鉴别疾病状态的方法和设备 - Google Patents

使用生物标记鉴别疾病状态的方法和设备 Download PDF

Info

Publication number
CN101479599A
CN101479599A CNA2007800237208A CN200780023720A CN101479599A CN 101479599 A CN101479599 A CN 101479599A CN A2007800237208 A CNA2007800237208 A CN A2007800237208A CN 200780023720 A CN200780023720 A CN 200780023720A CN 101479599 A CN101479599 A CN 101479599A
Authority
CN
China
Prior art keywords
status
biomarker
data
biomarker data
negative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800237208A
Other languages
English (en)
Chinese (zh)
Inventor
G·F·兰达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROVISTA DIAGNOSTICS LLC
Original Assignee
PROVISTA DIAGNOSTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROVISTA DIAGNOSTICS LLC filed Critical PROVISTA DIAGNOSTICS LLC
Publication of CN101479599A publication Critical patent/CN101479599A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
CNA2007800237208A 2006-05-01 2007-04-25 使用生物标记鉴别疾病状态的方法和设备 Pending CN101479599A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/381,104 US20070255113A1 (en) 2006-05-01 2006-05-01 Methods and apparatus for identifying disease status using biomarkers
US11/381,104 2006-05-01

Publications (1)

Publication Number Publication Date
CN101479599A true CN101479599A (zh) 2009-07-08

Family

ID=38648787

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800237208A Pending CN101479599A (zh) 2006-05-01 2007-04-25 使用生物标记鉴别疾病状态的方法和设备

Country Status (13)

Country Link
US (5) US20070255113A1 (enExample)
EP (2) EP2016405B1 (enExample)
JP (1) JP2009535644A (enExample)
KR (1) KR20090024686A (enExample)
CN (1) CN101479599A (enExample)
AU (1) AU2007248299A1 (enExample)
BR (1) BRPI0711148A2 (enExample)
CA (1) CA2650872C (enExample)
IL (1) IL195054A0 (enExample)
MX (1) MX2008013978A (enExample)
RU (1) RU2008147223A (enExample)
WO (1) WO2007130831A2 (enExample)
ZA (1) ZA200809968B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768448A (zh) * 2012-07-13 2015-07-08 昂热大学 用于提供可靠的非侵入式诊断测试的方法
CN106415563A (zh) * 2013-12-16 2017-02-15 菲利普莫里斯生产公司 用于预测个体的吸烟状况的系统和方法
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
EP2329260A4 (en) * 2008-03-04 2011-08-03 Ridge Diagnostics Inc DIAGNOSIS AND MONITORING OF DEPRESSIVE DISORDERS BASED ON A PLURALITY OF BIOMARKER PANELS
JP5658571B2 (ja) * 2008-03-12 2015-01-28 リッジ ダイアグノスティックス，インコーポレイテッド うつ障害をモニタリングするための炎症バイオマーカー
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
JP5781436B2 (ja) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
WO2010059709A2 (en) 2008-11-18 2010-05-27 Ridge Diagnostics, Inc. Metabolic syndrome and hpa axis biomarkers for major depressive disorder
WO2011025953A1 (en) * 2009-08-28 2011-03-03 Lexicor Medical Technology, Llc Systems and methods to identify a subgroup of adhd at higher risk for complicating conditions
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US20150127378A1 (en) * 2012-02-11 2015-05-07 Yougene Corp. Systems for storing, processing and utilizing proprietary genetic information
JP6075973B2 (ja) * 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
CN104822827B (zh) 2012-12-06 2020-01-21 干细胞生物科技公司 Lgr5+体干细胞
EP2746770A1 (en) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
US11699527B2 (en) * 2013-03-14 2023-07-11 Otraces, Inc. Method for improving disease diagnosis using measured analytes
US20140275294A1 (en) * 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
CN103279655A (zh) * 2013-05-20 2013-09-04 浙江大学 一种恶性肿瘤放化疗规范符合度的评估方法
AU2014268417A1 (en) 2013-05-23 2015-11-26 Iphenotype Llc Methods and systems for assisting persons, product providers and/or service providers
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3103046B1 (en) 2014-02-06 2020-03-25 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
AU2015243857A1 (en) * 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
JP6952056B2 (ja) * 2016-01-22 2021-10-20 オートレイシーズ, インク.Otraces, Inc. 疾患診断を改善するシステム及び方法
US11594311B1 (en) 2016-03-31 2023-02-28 OM1, Inc. Health care information system providing standardized outcome scores across patients
US11957897B2 (en) 2016-04-22 2024-04-16 Newton Howard Biological co-processor (BCP)
CN110366558A (zh) 2016-10-28 2019-10-22 班扬生物标记公司 针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
US20190302119A1 (en) * 2018-03-27 2019-10-03 Lawrence Abraham Cancer Diagnostic Metastasis Panel
US11967428B1 (en) * 2018-04-17 2024-04-23 OM1, Inc. Applying predictive models to data representing a history of events
LU100835B1 (en) * 2018-06-13 2019-12-13 Univ Muenster Westfaelische Wilhelms Novel biomarkers for recurrent tonsillitis
US11862346B1 (en) 2018-12-22 2024-01-02 OM1, Inc. Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20200395097A1 (en) * 2019-05-30 2020-12-17 Tempus Labs, Inc. Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
TWI740647B (zh) * 2020-09-15 2021-09-21 宏碁股份有限公司 疾病分類方法及疾病分類裝置
US20220223231A1 (en) * 2021-01-14 2022-07-14 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Improved Prognostics in Medical Imaging
KR102671925B1 (ko) * 2022-03-03 2024-06-03 인제대학교 산학협력단 파킨슨병 진단 방법 및 그 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197532B1 (en) * 1998-01-22 2001-03-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis and detection of breast cancer and other cancers
US6882990B1 (en) * 1999-05-01 2005-04-19 Biowulf Technologies, Llc Methods of identifying biological patterns using multiple data sets
US20020115070A1 (en) * 1999-03-15 2002-08-22 Pablo Tamayo Methods and apparatus for analyzing gene expression data
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
AU2002339841A1 (en) * 2001-07-13 2003-01-29 Dana-Farber Cancer Institute, Inc. Leukemogenic transcription factors
WO2003041562A2 (en) * 2001-11-14 2003-05-22 Whitehead Institute For Biomedical Research Molecular cancer diagnosis using tumor gene expression signature
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2499636A1 (en) * 2002-04-01 2003-10-16 Phase-1 Molecular Toxicology, Inc. Liver necrosis predictive genes
US20050176057A1 (en) * 2003-09-26 2005-08-11 Troy Bremer Diagnostic markers of mood disorders and methods of use thereof

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768448A (zh) * 2012-07-13 2015-07-08 昂热大学 用于提供可靠的非侵入式诊断测试的方法
US9996671B2 (en) 2012-07-13 2018-06-12 Universite D'angers Method for providing reliable non-invasive diagnostic tests
CN106415563A (zh) * 2013-12-16 2017-02-15 菲利普莫里斯生产公司 用于预测个体的吸烟状况的系统和方法
CN106415563B (zh) * 2013-12-16 2020-06-05 菲利普莫里斯生产公司 用于预测个体的吸烟状况的系统和方法
US11127486B2 (en) 2013-12-16 2021-09-21 Philip Morris Products S.A. Systems and methods for predicting a smoking status of an individual
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法

Also Published As

Publication number Publication date
IL195054A0 (en) 2009-08-03
AU2007248299A1 (en) 2007-11-15
US20210041440A1 (en) 2021-02-11
KR20090024686A (ko) 2009-03-09
EP2016405B1 (en) 2017-09-27
US20070254369A1 (en) 2007-11-01
EP2016405A4 (en) 2012-10-03
CA2650872C (en) 2018-04-24
EP2016405A2 (en) 2009-01-21
WO2007130831A3 (en) 2008-10-30
MX2008013978A (es) 2009-02-19
US20110077931A1 (en) 2011-03-31
JP2009535644A (ja) 2009-10-01
CA2650872A1 (en) 2007-11-15
EP3318995A1 (en) 2018-05-09
ZA200809968B (en) 2009-08-26
RU2008147223A (ru) 2010-06-10
US20130060549A1 (en) 2013-03-07
WO2007130831A2 (en) 2007-11-15
BRPI0711148A2 (pt) 2011-08-23
US20070255113A1 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
US20210041440A1 (en) Methods and apparatus for identifying disease status using biomarkers
Matthey Calculating clinically significant change in postnatal depression studies using the Edinburgh Postnatal Depression Scale
Wurst et al. Understanding asthma-chronic obstructive pulmonary disease overlap syndrome
Marshall et al. The association between maternal height, body mass index, and perinatal outcomes
Caswell‐Smith et al. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease
Wong et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort
Schaff et al. Novel centrifugal technology for measuring sperm concentration in the home
Wright et al. New-onset depression among children, adolescents, and adults with hidradenitis suppurativa
Araujo et al. Measurement properties of the craniocervical flexion test: a systematic review
Janes et al. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value
KR20150079641A (ko) 동적 네트워크 바이오마커의 검출 장치, 검출 방법 및 검출 프로그램
Philibert et al. AHRR methylation is a significant predictor of mortality risk in Framingham Heart Study
Oosterhuis et al. The science of systematic reviewing studies of diagnostic tests
CN116779077A (zh) 基于体检标志物构建生物学年龄及衰老评价的方法及系统
Aleem et al. Do cervical spine surgery patients recall their preoperative status?: A cohort study of recall bias in patient-reported outcomes
Knight et al. Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome
Ferguson et al. Quantification of a meaningful change in low back functional impairment
Freedman et al. Time‐dependent changes in placental mRNA expression after delivery due to delayed specimen collection
Mussavi Rizi et al. Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injury
Kraut et al. Re-evaluation of total CO2 concentration in apparently healthy younger adults
Sun et al. The association between inflammation-related biomarkers and the subtypes of cancer-related cognitive impairment in colorectal cancer patients: A latent profile analysis
Daya Characteristics of good causation studies
Lan et al. Comparison of the diagnostic accuracies of various biomarkers and scoring systems for sepsis: A systematic review and Bayesian diagnostic test accuracy network meta-analysis
Ahern Pharmacoepidemiology in pharmacogenetics
WO2009108196A1 (en) Methods and apparatus for identifying disease status using biomarkers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090708